We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 21, 2022

Reassessment of 4-Year Efficacy Outcomes of Adjuvant Nivolumab vs Ipilimumab for Stage III Melanoma per AJCC-8 Staging Criteria

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
Eur. J. Cancer 2022 Sep 01;173(2022)285-296, J Larkin, J Weber, M Del Vecchio, H Gogas, AM Arance, S Dalle, CL Cowey, M Schenker, JJ Grob, V Chiarion-Sileni, I Márquez-Rodas, MO Butler, AM Di Giacomo, MR Middleton, L De la Cruz-Merino, P Arenberger, V Atkinson, A Hill, LA Fecher, M Millward, NI Khushalani, P Queirolo, GV Long, M Lobo, M Askelson, PA Ascierto, M Mandalá

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading